MOTS-C

For the 20 mg vial, MOTS-C is described using the same core ‘exercise-mimetic’ framework: it functions as a metabolic stress signal that activates AMPK and pushes metabolism toward greater fuel utilization and less storage. The protocol explains AMPK activation through folate-cycle inhibition leading to AICAR accumulation, then describes downstream effects including enhanced glucose uptake, increased fatty-acid oxidation, and improved mitochondrial respiration, with reduced gluconeogenesis and fat storage. It also notes that MOTS-C can translocate to the nucleus in stress states and upregulate antioxidant and stress-response genes (mitochondria-to-nucleus retrograde signaling). The page links these mechanisms to preclinical findings across obesity, insulin resistance, menopausal metabolic decline models, and age-related frailty, and it cites broader interest in mTOR/inflammatory modulation for healthspan research. The protocol emphasizes that human clinical evidence is limited; a modified analog is noted as tolerable in early-phase testing, but MOTS-C itself remains investigational.